LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Britain Courts Anthropic Amid US Defense Department Dispute 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
BASEL, Switzerland and CAMBRIDGE, Mass., Nov. 21, 2016 -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced two presentations during the 58th American Society of Hematology (ASH) Annual Meeting taking place in San Diego, CA on December 3rd-6th, 2016.
The two presentations will highlight recent work in re-creating the natural condition of hereditary persistence of fetal hemoglobin (HPFH) that is protective in sickle cell disease and beta thalassemia. The presentations will describe the ability to re-create specific HPFH gene variants in the intended target tissue, human primary CD34+ stem cells, and the effect of these gene variants at re-creating the expression of protective fetal hemoglobin. Additional data on progress towards filing an IND or CTA will also be presented.
“We are excited by our progress and we remain focused on our goal of bringing potentially transformative therapies to patients with beta thalassemia and sickle cell disease,” said Dr. Rodger Novak, CEO of CRISPR Therapeutics. "We look forward to discussing data from our recent work at the upcoming ASH conference.”
Details of the presentations are as follows:
| Title: | CRISPR/Cas9 – Mediated Genome Editing of Human CD34+ Cells Upregulate Fetal Hemoglobin to Clinically Relevant Levels in Single Cell-Derived Erythroid Colonies (Abstract #3623) |
| Presenter: | Bibhu Mishra, Ph.D., (Title)), CRISPR Therapeutics |
| Date: | Monday, December 5, 2016, 6:00-8:00PM PT - Hall GH (San Diego Convention Center) |
| Session: | 112. Thalassemia and Globin Gene Regulation: Poster III |
| Title: | Re-Creating Hereditary Persistence of Fetal Hemoglobin (HPFH) to Treat Sickle Cell Disease (SCD) and β-Thalassemia (Abstract #4708) |
| Presenter: | Bill (Sven Ante) Lundberg, M.D., M.B.A, Chief Scientific Officer, CRISPR Therapeutics |
| Date: | Monday, December 5, 2016, 6:00-8:00PM PT - Hall GH (San Diego Convention Center) |
| Session: | 801. Gene Therapy and Transfer: Poster III |
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform.
MEDIA CONTACTS: Jennifer Paganelli W2O Group for CRISPR 347-658-8290 [email protected] INVESTOR CONTACT: Chris Brinzey Westwicke Partners for CRISPR 339-970-2843 [email protected]
